It began with an audacious idea…


Cellarity was founded in 2017 at Flagship Pioneering's innovation foundry, Flagship Labs. Cellarity’s journey began with brainstorming sessions between Flagship Pioneering Founder and CEO Noubar Afeyan, Partner Avak Kahvejian and Senior Associate Nick Plugis. They focused on the complex networks embedded in every cell and the potential for computation to target the full complexity of disease biology to accelerate medical breakthroughs. Currently, the dominant approach to drug discovery involves structure-based drug design around single-target drivers of disease. This paradigm has been successful at delivering many medicines in the past decades but leaves many diseases without treatment options or clear targets. This approach also risks overlooking the potent networked features of disease biology. This contributes to the failure of many promising pre-clinical assets as they progress through human trials – with only one in ten drug candidates ultimately reaching the patient.

The Flagship team recognized that powerful new biological and computational technologies exist to perturb and quantitate virtually any cellular or molecular component. They also envisioned that these technologies can generate the data necessary to unravel biological complexity. This strategy has the promise to produce drug candidates with improved fidelity through the discovery and development pipeline.

Thus, Cellarity was created – a first-of-its-kind therapeutics company that is discovering and developing medicines by studying and altering cell behaviors. Cellarity has developed a powerful, generalizable platform harnessing single-cell technologies and machine learning to unveil the network state of a given cell, defining the cell's behavior. Cellarity's platform digitizes and quantifies cellular behaviors, unravels the network dynamics that govern those behaviors, and generates medicines that can direct them. These medicines are rationally designed to alter the cell behaviors that drive disease, obviating the need for lengthy and costly high throughput screening.

With the unique ability to discover drugs based on cellular behavior, Cellarity’s goal is to dramatically increase the success rate and speed of drug discovery.


Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $34 billion in aggregate value. To date, Flagship is backed by more than $4.4 billion of aggregate capital commitments, of which over $1.9 billion has been deployed toward the founding and growth of its pioneering companies alongside more than $10 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics, Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology, Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).